Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus intensive chemotherapy for genetically defined acute myeloid leukemia
NL-OMON60022Phase 1Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of revumenib in acute myeloid leukemia (AML), sponsored by Syndax Pharmaceuticals. Started Jul 2025; status: active, not recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON60022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60022.